At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, argued in favor of minimal residual disease (MRD) testing for patients with multiple myeloma, in both a research setting and in clinical practice.
